Leerink Partners Increases Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00
Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in ...
Strategic Acquisition of Life Molecular Imaging Boosts Lantheus’ Position in Alzheimer’s Radiodiagnostic Market
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Stay Ahead of the ...
Vir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth Outlook
Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...